PARTNERING WITH BOEHRINGER INGELHEIM

The development of new treatment options for neuropsychiatric diseases is a key priority for Boehringer Ingelheim, evidenced by the innovative work in these areas of both its collaboration partners and the company’s own highly experienced research and development professionals.

Indications:
Neuropsychiatric diseases including
- Alzheimer’s disease (e.g. cognitive impairment; non-cognitive symptoms)
- Schizophrenia (e.g. negative symptoms and/or cognitive impairment)
- Depression (e.g. treatment-resistant depression)
- Impulsivity disorders (e.g. substance use disorder; obsessive-compulsive disorder; borderline personality disorder)

Specific partnering priorities:
- Innovative approaches to modulate maladaptive neurocircuits and neural network activity; ideally, the proposed therapeutic modality will include quantifiable biomarkers
- Complementary non-drug approaches (e.g. digital therapeutics)

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:

Dr. Laura Corradini
laura.corradini@boehringer-ingelheim.com

Dr. Christian Thomsen
christian.thomsen@boehringer-ingelheim.com